This message contains images. If you don't see images, click here to view.
Click here to advertise in this news brief.




Mobile version  RSS  Subscribe  Unsubscribe  Archive  Media Kit

Home   About AST   Education   Meetings & Events   Public Policy   Contact Us   Nov. 29, 2012

 



The future of heart transplantation
American Journal of Transplantation (subscription required)    Share    Share on FacebookTwitterShare on LinkedinE-mail article
The field of heart transplantation has seen significant progress in the past 40 years. However, the breakthroughs in long-term outcome have seen stagnation in the past decade. Through advances in genomics and transcriptomics, there is hope that an era of personalized transplant therapy lies in the future. To see where heart transplantation truly fits into the long term, searching for and understanding the alternative approaches for heart failure therapy is both important and inevitable. More

Iso-Tex Diagnostics, Inc.

• We are an FDA licensed manufacturer.
• We label peptides, monoclonal antibodies, reagents, chemical   and proteins for cancer treatments.
• Our above products can be labeled with radioisotopes such as   I-125, I-131, P32, Tc99m, Y90 and AC-225.
• We have a multicurie isotope license and an animal facility.
 SOCIETY NEWS


Wiley Books offers 40 percent discount to AST members
AST    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Wiley Blackwell is offering AST members a special holiday discount of 40 percent on virtually all of Wiley's print books, an increase from the standard discount of 25 percent. AST members have purchased more than 130 books through the discount program so far. The holiday special will be active from Nov. 26, through Jan. 11. For further information, click here.

Call for 2013 AST Board nominations
AST    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Open positions on the 2013-2014 Board include president-elect (one-year term), and three councilors-at-large (each for three-year terms). The term of service begins with the rotation of the board at the annual members business meeting scheduled for May 20, 2013 at the American Transplant Congress. Click here to submit a nomination. Completed nominations must be submitted to the AST National Office by Friday, Nov. 30 at 5 p.m. EST.

C1qScreen™: A New Research Tool for AMR Risk
Identify Antibodies That May Compromise Graft Survival
  • Detect Presence of Complement Fixing Antibodies
  • Investigate risk of developing Antibody Mediated Rejection (AMR)
Request a Complimentary Sample Kit!
FREE SAMPLE

For Research Use Only. Not for use in diagnostic procedures.


Last chance to take 50 percent off regular CEOT registration
AST    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Fifty percent off regular registration ends Friday, Nov. 30. Register now to take advantage of this excellent deal. The upcoming Cutting Edge of Transplantation (CEOT) meeting is a must-attend event that will tackle some of the challenges and controversies related to B cells and antibodies in transplantation. The three-day meeting includes talks from more than 30 experts in the field of transplantation, plus networking opportunities and abstract presentations. Register now.

Free on demand webcasts for AST members: ATC highlights and KPD Consensus Conference
AST    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Education when you want it, in less than 60 minutes! The Timely Topics in Transplantation on demand webcast series includes ATC 2012 highlights in infectious disease, live donation, multiorgan transplantation and thoracic transplantation. These webcasts are free to AST members and can be viewed any time, at your leisure. Non-members may view the webcasts for only $25 each. Coming soon: Hepatitis management and the challenges of resistance.

 TRANSPLANT NEWS


HeartWare LVAD approved by FDA for transplant patients
Forbes    Share    Share on FacebookTwitterShare on LinkedinE-mail article
The U.S. Food and Drug Administration said that it has granted approval to the HeartWare Ventricular Assist System for use in heart failure patients waiting for a transplant. Approval of the device had been expected after the FDA's Circulatory System Devices panel recommended approval of the device earlier this year.

Related articles:
FDA approves HeartWare LVAD for heart failure (Medpage Today - subscription required)
FDA approves HeartWare pump for heart failure patients (Reuters via MSNBC)
More

Age-based disparity in outcomes of intestinal transplants in pediatric patients
American Journal of Transplantation (subscription required)    Share    Share on FacebookTwitterShare on LinkedinE-mail article
In a recent study, outcomes of intestinal transplants for pediatric patients were examined using the United Network for Organ Sharing data from 1987 to 2009. The difference in graft survival between isolated intestine transplant (ITx) and L-ITx was significant at one and three years. Isolated ITx should be considered early before the onset of liver disease in children older than 2 with intestinal failure but is not advantageous in patients younger than 2. More



Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts
Liver Transplantation (subscription required)    Share    Share on FacebookTwitterShare on LinkedinE-mail article
The role of donor-specific anti-human leukocyte antigen antibodies (DSAs) that develop late after living donor liver transplantation is unknown. In a recent study, 79 pediatric recipients who had good graft function and underwent protocol liver biopsy more than 5 years after transplantation (median = 11 years, range = 5-20 years) were reviewed. The high prevalence of graft fibrosis and anti–class II DSAs in late protocol biopsy samples suggests that humoral alloreactivity may contribute to the process of unexplained graft fibrosis late after liver transplantation. More


Athena Diagnostics

Genetic testing can be a cost-effective way to increase the number of living related donor transplants. Mutational analysis may help direct long-term treatment plans, including pre-operative screening of potential kidney transplant recipients and living related donors.
WAVES by Waters Medical Systems
✓ Hypothermic preservation of a single kidney using physiologic pulsatile preservation and membrane oxygenation: a proven technology from Waters Medical Systems (more than 40 years clinical experience) ✓ Simplifies the perfusion process (provides more options to view, chart, and trend data, offers web-based remote monitoring, and a transportable design)
✓ Meets or exceeds current FDA standards and AOPO and UNOS Preservation Guidelines.
MNX: Organ Transportation
When it comes to saving lives, MNX understands organ transplant logistics. Every shipment is urgent, and every step critical. That’s why MNX offers specialty services that are tailored for organ transportation. From expedited ground service to charter flights, MNX has the proven experience and operational resources you can count on.


Neoadjuvant transarterial chemoembolization on tumor recurrence and patient survival after liver transplantation for hepatocellular carcinoma
Clinical Transplantation (subscription required)    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Transarterial chemoembolization (TACE) has gained wide acceptance as a bridge to liver transplantation (LT) in patients with hepatocellular carcinoma (HCC). A recent analysis compared long-term results with and without neoadjuvant TACE and to identify subgroups, which particularly benefit from TACE. Results suggest that TACE lowers the HCC recurrence rate in patients inside the Milan and UCSF criteria. More

The pits and pearls in translating operational tolerance biomarkers into clinical practice
Current Opinion in Organ Transplantation (subscription required)    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Major advances have been made with respect to the understanding of mechanisms and the process of discovery and early validation of peripheral blood biomarkers for operational transplant tolerance both in kidney and liver transplantation. Prospective trials and organ integrative studies are now needed to further develop these biomarkers for future clinical application in addition to expanding novel approaches such as the investigation of miRNAs to better understand the tolerance mechanisms. More

Rho-kinase-dependent pathway mediates the hepatoprotective effects of sorafenib against ischemia/reperfusion liver injury in rats with nonalcoholic steatohepatitis
Liver Transplantation (subscription required)    Share    Share on FacebookTwitterShare on LinkedinE-mail article
During liver transplantation, nonalcoholic steatohepatitis (NASH) aggravates ischemia/reperfusion (IR) injury by activating various kinases and subsequently releasing cytokines and chemokines. Nonetheless, the effect of the multikinase inhibitor sorafenib on IR liver injury in rats with NASH has never been explored. A recent study was designed to determine this effect and associated mechanisms in NASH rats. The study demonstrated that the multikinase inhibitor sorafenib protects NASH rats from IR injury by interfering with the inflammation, necrotic and apoptotic responses causing leukocyte-dependent hepatic microcirculatory dysfunction. More

Comparison of chest radiograph scoring to lung weight as a quantitative index of pulmonary edema in organ donors
Clinical Transplantation (subscription required)    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Quantification of the degree of pulmonary edema in organ donors is useful for assessing the clinical severity of pulmonary edema, determining response to therapy and as an endpoint for therapeutic trials. Currently, there is no accurate non-invasive method for assessing the degree of pulmonary edema. More

Influenza vaccination in solid-organ transplant recipients
Current Opinion in Organ Transplantation (subscription required)    Share    Share on FacebookTwitterShare on LinkedinE-mail article
The administration of influenza vaccination is strongly recommended in solid-organ transplant recipients and their relatives. Further research is needed for improving the immunogenicity of influenza vaccine in this population. More

Long-term outcomes worse in spontaneous survivors of non-acetaminophen liver failure than transplant recipients
Healio    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Spontaneous survivors of non-acetaminophen acute liver failure have significantly poorer survival rates at two years than patients with acute liver failure who received transplantation, according to data presented at The Liver Meeting. More
 



AST eNews

Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Courtney Hodges, Content Editor, 972.402.2604   
Contribute news


This edition of the AST eNews was sent to ##Email##. To unsubscribe, click here.

Recent issues
Nov. 21, 2012
Nov. 15, 2012
Nov. 8, 2012
Nov. 1, 2012






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063